Tenax Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Tenax Therapeutics Inc TENX.OQ reported a quarterly adjusted loss of 27 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.83. The mean expectation of four analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -29 cents to -19 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Tenax Therapeutics Inc's reported EPS for the quarter was a loss of 27 cents​.

• The company reported a quarterly loss of $10.85 million.

• Tenax Therapeutics Inc shares had risen by 2.3% this quarter and lost 4.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Tenax Therapeutics Inc is $16.00, about 63.2% above its last closing price of $5.89

This summary was machine generated from LSEG data August 13 at 08:43 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)